CS/TPP纳米微胶囊的制备及其载药性能

利用离子凝胶法, 以三聚磷酸钠(TPP)为交联剂, 由壳聚糖(CS)制备了CS/TPP纳米微胶囊. 用红外光谱仪、扫描电镜和粒径分析仪进行了表征, 并以牛血清蛋白(BSA)作为模型药物, 考察了所制备的CS/TPP纳米微胶囊的包载和缓释性能. 结果表明, CS/TPP纳米微胶囊的红外光谱相对于CS和TPP的红外光谱发生了很大变化, 说明CS和TPP通过正负电荷吸引聚合成囊; 粒径分析表明, 离子凝胶法可以得到粒径约430 nm的均匀分散的壳聚糖纳米微胶囊, 经冷冻干燥后粒径变为300 nm左右; 微胶囊包封率最高可达79.74%, 模型药物的持续释放时间可达7 d以上.     

淫羊藿苷壳聚糖/明胶微球的制备及其体外释放研究

本试验以壳聚糖、明胶为载药基质,以中药淫羊藿苷为模拟药物,通过乳化交联的方法制备淫羊藿苷/壳聚糖/明胶微球。考察微球的理化特性,建立持续流动释放系统,检测了微球的体外释放特性和影响因素。微球的理化特性受工艺条件如搅拌速度、乳化剂用量、交联剂用量等因素影响。微球的体外释放速率与微球的粒径、交联度负相关,与载药量正相关。试验结果表明,壳聚糖、明胶可作为缓释微球的载体基质,微球制备工艺简单稳定,微球的释放速率可控,淫羊藿苷/壳聚糖/明胶微球是一种良好的药物释放体系。     

Ciprofloxacin Loaded Alginate/Chitosan and Solid Lipid Nanoparticles,Preparation, and Characterization

The aim of the present study was to develop controlled drug delivery systems based on nanotechnology. Two different nanocarriers were selected, chitosan-alginate nanoparticles as hydrophilic and solid lipid nanoparticles as lipophilic carriers. Nanoparticles were prepared and characterized by evaluating particle size, zeta potential, SEM pictures, DSC thermograms, percentage of drug loading efficiency, and drug release profile. The particle size of SLNs and Chi/Alg nanoparticles was 291 ± 5 and 520 ± 16. Drug loading efficiency of Chi/Alg and SLN particles were 68.98 ± 5.5% and 88 ± 4.5%. The drug release was sustained with chitosan-alginate system for about 45 hours whereas for SLNs >98% of the drug was released in 2 hours. Release profile did not change significantly after freeze drying of particles using cryoprotector. Results suggest that under in vitro condition chitosan/alginate systems can act as promising carriers for ciprofloxacin and may be used as an alternative system in sustained delivery of ciprofloxacin.     

壳聚糖/乙酰半胱氨酸纳米粒子的性质及体外释药性

制备了一种基于壳聚糖/乙酰半胱氨酸偶合物(CS-NAC)的新型巯基纳米粒子并进行了结构表征, 同时对纳米粒子的黏附性、溶胀性和药物释放进行了测试. 结果表明, 纳米粒子具有较小的粒径(140~210 nm)和正的表面电位(19.5~31.7 mV), 胰岛素的载药量达到13%~42%. 这些性质随着巯基含量的变化而变化. 与壳聚糖纳米粒子相比, 巯基壳聚糖纳米粒子表现出了更强更快的黏附性质. 体外释放研究结果表明, 巯基壳聚糖纳米粒子的胰岛素释放具有pH响应性. 在pH=6.8时, 15 min即能释放58.6 %的胰岛素; 而在pH=5.4时, 24 h内仅有不到40%的胰岛素被释放. 因此, CS-NAC纳米粒子用于胰岛素的黏膜给药体系具有很好的应用前景.     

具有垂直孔道的壳聚糖乳酸盐海绵的制备及体外释药模型的拟合分析

先将壳聚糖(CH)经乳酸改性制成壳聚糖乳酸盐(LCH)以改善其溶解性, 然后通过加入冰晶生长引导剂叔丁醇(TBA), 在特制的定向冷冻装置中冻结, 再经冷冻干燥后, 制成了一种圆柱形的海绵体, 其内部具有垂直方向上的孔道结构. 通过控制叔丁醇的浓度, 制备了具有不同孔径及孔隙率的海绵样品. 以红霉素为模型药物, 研究了具有自身降解溶蚀功能的LCH样品的体外释药模型, 结果表明, LCH样品的释药过程主要分为基体溶蚀控释和药物后扩散2个阶段. 其中基体控释阶段符合Couarraze释药模型.     

抗肿瘤药物在金属有机骨架中的装载及体外释放

以三乙胺直接加入法制备金属-有机骨架MOF-5, 采用X射线粉末衍射(XRD), 红外光谱(IR)和热重分析(TG)对所得样品进行表征. 分别以辣椒素和5-氟尿嘧啶(5-Fluouourail, 5-FU)为模型药物, 研究了MOF-5对2种药物的载药及体外释药性能. 通过将所得样品的XRD和IR谱图与标准谱图比对确定了样品的结构. TG结果表明, 所制备的MOF-5热稳定性良好. MOF-5对辣椒素的最高载入量达0.592 g/g载体, 对5-FU的最高载入量为0.315 g/g载体, 两种载药体系的体外释药均为明显的两相模式. 体外细胞毒性实验结果表明, MOF-5具有良好的生物相容性.     

BSA载药微囊的制备、表征及体外释放行为

采用复乳法-液中干燥法制备了一系列含有牛血清蛋白(BSA)的聚乙二醇-b-聚(6-(乙酸苄酯)-ε-己内酯-co-ε-己内酯(PEBCL)微囊.分别研究了聚合物结构以及制备条件对微囊粒径、载药量和包封率的影响,同时研究了载药微囊在pH=7.4的磷酸盐缓冲溶液中的体外释放行为.研究表明:微囊的平均粒径13～30 μm,微囊对BSA的载药量和包封率分别最高可以达到14.18%和75.90%,药物的释放行为可控,PEBCL微囊作为蛋白质类药物载体有望在临床上获得应用.     

可生物降解固体脂质纳米粒的制备、表征及药物的体外释放

以可生物降解材料硬脂酸为载体, 以葛根总黄酮为模型药物, 采用乳化蒸发-低温固化法制备固体脂质纳米粒. 采用透射电镜研究载药纳米粒形态, 激光粒度分析仪测定其粒径, X射线衍射仪进行物相鉴别, 并对纳米粒的包封率及体外释药特性等进行了研究. 分析结果表明, 所制备硬脂酸固态脂质纳米粒为类球实体, 粒径分布比较均匀, 平均粒径为(263.82±3.6) nm, 包封率为(67.53±0.12)%. X射线衍射分析证明药物以分子或细小粒子分散于脂质骨架中. 体外释药研究结果表明, 纳米粒体外释药先快后慢, 12 h累积释药50%, 包封于降解材料骨架内的药物通过骨架溶蚀缓慢释放. 药物的体外释放符合Higuchi方程.     

Preparation,Characterization, and In Vitro Release of Chloramphenicol Loaded Solid Lipid Nanoparticles

In the present contribution, solid lipid nanoparticles have been prepared from oil-in-water microemulsion, using various monoglycerides (monocaprate, monolaurate and monomyristin) as solid matrix, polyethylene glycol sorbitan monooleate (Tween 80) as emulsifier, and chloramphenicol as target drug. The morphology and microstructure of drug loaded SLNs were investigated by use of the transmission electron microscope (TEM) and x-ray diffraction (XRD) techniques. The pictures of TEM showed that SLNs are spherical particles, and the average diameters measured by dynamic light scattering (DLS) were under 100 nm. The crystallographic properties of them were characterized by XRD. It was found that chloramphenicol do not exist in crystalline state in SLN. Both drug-free and drug-loaded SLN existed in amorphous state. In addition, zeta potentials of SLNs were investigated. Zeta potentials of all the samples were around ?6 to ?23 mv. Further more, the core-shell model with drug enriched shell was proposed for the present system. Release kinetics of chloramphenicol from SLN showed a relative fast release in the initial several hours, and the release profile was accordance with the drug incorporation model we presented. Effects of types and concentration of lipids, and surface modifiers on drug release behavior were studied.     

Preparation and in vitro Release Test of Insulin Loaded W/O Microemulsion

A W/O microemulsion of Tween‐80‐Span‐80/n‐butylalcohol/ethyl‐oleate/H₂O to envelop insulin (INS) was prepared. In order to obtain the maximum solved water, the components of microemulsion to envelop INS were chosen with the pseudo‐ternary phase diagram and the influences of temperature, salinity as well as the pH on microemulsion areas also were investigated. To test the properties of the microemulsion, the conductance was used to divide O/W, W/O and BC regions, the dynamic light scattering to evaluate the particle diameters of microemulsion, the ¹²⁵I isotope tracing method to measure the release rate of INS loaded in W/O microemulsion, and the growth inhibitory effect test to appraise the cytotoxicity on human normal cells. Results show that W/O microemulsion forms when water content below 50% in the microemulsion system. The microemulsion region decreases slightly with the increase of temperature, salinity and the decrease of pH. However, the viscosity measurements along certainly selected dilution lines to the microemulsion indicate that no phase invert occurred. Diameter of microemulsion particle increases with the addition of INS, and the increase is sharp in the first 5 days then very slightly at 68.6 nm within a month. The INS loaded W/O microemulsion possesses eminent sustaining release efficiency and the cytostatic as well as cytotoxic assays illustrate that the microemulsion can be used as drug delivery at small dosage.     

肝靶向甘草次酸修饰的壳聚糖纳米粒子的合成和表征

合成了修饰甘草次酸的壳聚糖(GA-CTS), 采用离子交联法制备了GA-CTS纳米粒子. 该材料可能具有肝细胞主动靶向作用, 为进一步的肝靶向药物控释的研究奠定了基础.     

微乳液成核-离子交联制备阿司匹林/壳聚糖纳米微球及其体外释放行为

以自制阿司匹林为药物模型,壳聚糖(CS)为载体源,采用微乳液成核-离子交联法制备了阿司匹林/壳聚糖纳米缓释微球.分别用傅里叶变换红外(FTIR)光谱、场发射扫描电子显微镜(FESEM)、透射电子显微镜(TEM)、动态激光光散射(DLLS)、X射线粉末衍射(XRD)等表征了纳米微粒的化学组成、外观形貌、平均粒径和粒径分布、微球中壳聚糖的晶体结构以及阿司匹林的分布形态.结果表明,利用微乳液成核-离子交联法制备的阿司匹林/壳聚糖微球平均粒径约为88nm且粒径分布均匀,成核后壳聚糖结晶形态基本未变,阿司匹林以分子形态分布于微粒中,分子间未形成堆砌,为无定形态.采用UV-Vis分光光度计考察了微球的药物包封率、载药量,并对微球在生理盐水和葡萄糖溶液中的释药行为进行跟踪.结果表明,微球的载药量可达55%,药物包封率可达42%,实验条件下具有较好的药物缓释作用.     

毒死蜱/环糊精在锌铝类水滑石中插层的制备和性能

以层状锌铝类水滑石(ZAL)为主体,分别以磺丁基醚-β-环糊精(SBECD)和羧甲基-β-环糊精(CMCD)包结毒死蜱(CPF)为客体分子,分别在乙醇和N-甲基吡咯烷酮(NMP)溶剂条件下制备ZAL-SBECD-CPF和ZALCMCD-CPF插层材料,采用X射线粉末衍射(XRD)、傅里叶变换红外(FT-IR)光谱和热重-差热分析(TG-DTA)对其结构和热稳定性进行表征。结果表明, CPF/SBECD和CPF/CMCD均可成功在ZAL中插层,且在NMP溶剂条件下合成样品的衍射峰强度要强;插层CPF分子有较高热稳定性。此外,还对ZAL-SBECD-CPF和ZAL-CMCD-CPF在pH = 5.0, 6.8的环境条件下的释放行为进行研究和对比。结果发现, ZAL-SBECD-CPF样品几乎没有缓释性能,而ZAL-CMCD-CPF有一定的缓释性能,这与客体分子在层间排布方式不同有关。两种样品在pH = 6.8条件下的释放百分率均高于pH = 5.0,这与释放环境和环糊精(CD)分子结构密切相关。ZAL-CMCD-CPF的释放行为可很好的用二级动力学方程和parabolic diffusion模型来描述,说明药物客体分子释放主要受扩散过程控制。研究结果将有助于开发ZAL-CMCD-CPF在农药制剂方面的应用价值。     

Preparation and Characterization of Poly (D,L-Lactide-co-Glycolide) (PLGA) Nanoparticles Loaded with Linamarin for Controlled Drug Release

Poly (D,L-lactide-co-glycolide) nanoparticles loaded with linamarin as a model drug were successfully prepared using the double emulsion solvent evaporation technique. The physicochemical characterization of the formulated nanoparticles revealed that they were spherical, nonaggregated, and negatively charged, with good drug encapsulation efficiencies (>50%) and average particle sizes <200 nm. Interestingly, all the nanoparticles exhibited dibasic release profiles with a starting burst release within the first 8 h, followed by a controlled release phase lasting four days. Thus, linamarin-loaded nanoparticles indicate a promising candidate for controlled drug release applications.     

双重载药多层海藻酸盐-壳聚糖缓释微球的制备及体外释放

采用滴注法将海藻酸钠与钙离子交联,制成负载血管内皮生长因子(VEGF)的藻酸钙核心球,利用层层自组装技术在核心球的表面依次包覆壳聚糖、海藻酸和壳聚糖,壳聚糖中负载万古霉素(VAN),形成多药载药缓控体系.采用正交实验考察海藻酸钠浓度、钙离子浓度及壳聚糖浓度对VEGF和VAN的药物包封率和载药量的影响,优化了制备工艺.采用扫描电子显微镜观察多层微球的表面、截面形貌及粒径,采用傅里叶变换红外光谱检测海藻酸盐与壳聚糖的自组装情况,分别采用酶联免疫吸附(ELISA)双抗体夹心法和紫外分光光度法检测VEGF和VAN的包封率、载药量及体外释放情况.结果表明,海藻酸钠最优浓度为0.04g/mL,氯化钙最优浓度为0.15g/mL,壳聚糖最优浓度为0.01g/mL.微球光滑圆整,均质实心,直径900~1100μm,VEGF的包封率达61.31%,VAN的包封率为3.48%.体外释放实验结果表明,VEGF缓释时间为15.5d,并出现2个释放高峰;VAN缓释时间为4.5d,释药情况平稳持续,无明显突释.双重载药多层包覆微球兼具控制感染和促进血管生成两种潜能,有望应用于组织工程骨的基础研究和临床实践.     

新型介孔羟基磷灰石/壳聚糖-万古霉素药物释放系统复合材料的制备及体外抗菌和成骨能力

采用冷冻干燥法合成了介孔羟基磷灰石(HA)/壳聚糖(CS)-万古霉素(VCM)药物释放系统复合材料, 利用SEM, XRD和FTIR等方法对材料进行了表征. 结果证实CS与HA混合复合材料具有良好的孔径和孔隙率, 万古霉素吸附于复合材料的表面和内部. 细胞毒性实验[噻唑蓝(MTT)比色法]结果表明, 材料可以促进成骨细胞增殖且具有良好的细胞相容性. 体外抑菌实验结果证实此材料可长时间抑制耐甲氧西林金葡菌(MRSA)的生长, 具有良好的抑菌和杀菌能力. 细胞黏附实验结果表明, 成骨细胞附着于材料表面增殖并通过孔道延伸. 实时聚合酶链式反应(RT-PCR)实验结果表明, 在成骨相关标志产物胶原蛋白-1(COL-1)及骨形态发生蛋白-2(BMP-2)基因上均有较高的表达, 表明材料在体外可以促进成骨细胞生长, 具有良好的成骨能力.     

壳交联pH响应型PLGA载药微球的制备与研究

首先采用一次乳化法制备出PLGA[聚(乳酸-羟基乙酸)]纳米微球,并通过静电吸附将阳离子聚合物壳聚糖修饰到PLGA微球表面,然后以香草醛为交联剂对壳聚糖进行化学交联,得到一种壳交联的p H响应型纳米微球(PCV),微球粒径为(277.60±38.01)nm,表面电位为(21.60±4.51)m V.微球稳定性评价结果显示微球在24 h内粒径变化较小;流式细胞仪检测显示细胞对PCV微球的摄取量比未经修饰的PLGA微球的摄取量高;空白微球细胞毒性实验表明在空白微球浓度小于80μg/m L时细胞的存活率达93.24%.以多西他赛(DTX)为模型药物进行包载,该纳米微球DTX的载药率为7.48%,包封率为34.98%;体外药物释放实验显示,该微球在p H=5.0环境下孵育90 h的药物积累释放率达58.66%,而在p H=7.4的环境下的药物积累释放率为50.63%;此外,载DTX微球毒性试验结果表明该载药微球对A549肺癌细胞有较强的杀伤作用,其IC50值可达0.0009μg/m L.     

PLGA/O-CMC载药纳米粒子的体外释药行为研究

本文以聚乳酸-乙醇酸共聚物(PLGA)和自行制备的O-羧甲基壳聚糖(O-CMC)为原料,以5-氟尿嘧啶(5-FU)为抗癌药物模型,采用自身设计的改良复乳法制备了载药纳米微粒。微粒平均粒径为98.5nm,粒径分布指数为0.192,粒子表面∈电位为61．48eV,载药率高达18．9％,包封率为86％。然后用SEM动态监测载药纳米粒子降解过程中表面形貌的变化,并连续追踪粒子降解过程中的质量损失和降解介质的pH变化。载药纳米粒子在PBS中的释药行为研究表明：(1)前12h的释药动力学符合Huguchi方程,具有一级释放特性;(2)在20天内的释药动力学符合零级释放特性。     

Comparison of BSA Release Behavior from Electrospun PLGA and PLGA/Chitosan Membranes

In order to encapsulate and controlled-release bioactive proteins,three fibrous membranes,i.e.,poly(L-lactide-co-glycolide)(PLGA),hybrid PLGA and chitosan(H-PLGA/CS),and core/shell PLGA/CS (C-PLGA/CS),were produced by emulsion electrospinning,co-electrospinning and coaxial electrospinning,respectively.Bovine serum albumin(BSA) was selected as a model protein.The loading efficiency of BSA in the PLGA membrane was 1.56%,lower than those of H-PLGA/CS(5.98%) and C-PLGA/CS(4.80%).BSA release profiles from the th...     

壳聚糖及其衍生物基因载体的研究进展

壳聚糖是一种天然的生物可降解性,生物相容性好而且安全无毒的多糖,因而它成为基因治疗载体研究的热点。本文就近年来壳聚糖及其衍生物作为基因载体转染的研究进展和现状作简要的综述,并对转染率的影响因素如壳聚糖的分子量、粒径、脱乙酰度等进行着重介绍。